BIO-002 trial is a Phase I clinical trial to assess the safety and immunogenicity of the RH5.1 soluble protein vaccine in Matrix-M™ adjuvant using two dosing regimens in healthy UK adults. This vaccine has been developed to protect against blood-stage Plasmodium falciparum malaria. This trial is taking place at Royal Hallamshire Hospital (Sheffield Teaching Hospital NHS FT) led by Dr Ruth Payne (PI in Sheffield) and Dr Angela Minassian (CI in Oxford). This trial is sponsored by University of Oxford and is funded by the MRC Developmental Pathway Funding Scheme (DPFS).
Sarah Silk, Senior Clinical Trials Immunologist and Dimitra Pipini, Clinical Trials Research Assistant from University of Oxford visited the study site laboratories on 11th May 2023. The visit included meeting the lab team from University of Sheffield to run through sample handling and documentation procedures as well as review of GCP compliance and study lab set up. The visit was a great success with lab and team ready for study start. This trial will provide important evaluation of delayed boost vaccination regimens and impact of vaccine dose.
For more information on the BIO-002 study, please click here.
